glp 1 retatrutide Triple Agonist (GLP-1/GIP/GCG) New GLP-1 obesity drug, retatrutide,
Description
Health at every size [archived link] is one approach suggested for making healthcare more inclusive
Pre-existing conditions also influence eligibility and monitoring needs
In preclinical models of AD, GLP-1 decreases A toxicity in vitro (During et al., 2003
An open question has been how Notch signaling modulates FBF activity to promote stem cell self-renewal
Harris, E
This suggests GLP-1 is the key player for appetite suppression and weight loss, with GIP providing enhancement rather than being equally important
